Caris Life Sciences, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$6.7
Forward price-to-earnings vs peers
Base case. Range ~$5.5–$10. Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings.
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Caris Life Sciences, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $990m. Free-cash-flow margin rose to 12.5% from -26.3% a year earlier. Operating margin widened to 15.5% from -32.6%. It passes 3 of our 5 financial-health checks. Our price-to-earnings vs peers value is $7.73 a share, against a share price of $31.53.
Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Caris Life Sciences, Inc.'s trailing-twelve-month revenue grew 85.4% year on year, with a free-cash-flow margin of 12.5%.
Current signal Revenue growth decelerating: TTM revenue growth slowed to 85.4% (-15.1pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The company also guided to revenue growth of 27.00 to 28.00 for the full year 2026; clinical therapy selection volume growth of 20.00 for the full year 2026.
We value Caris Life Sciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.74 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$4.4 ~$2.6–$5.8 | Left out: out of range vs price (0.14x) |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$6.7 ~$5.5–$10 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$3.3 ~$3.3–$9.1 | Left out: out of range vs price (0.10x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$6.7 ~$5.5–$10 | 1 model |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Caris Life Sciences, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2025 |
|---|---|
| Share price | $26.98 |
| Market value | $4.5bn |
| + Net debt (− = net cash) | −$417m |
| Enterprise value | $4.1bn |
| Multiples | |
| Price / sales | 5.6x |
| Price / earnings | — |
| Price / free cash flow | 67.4x |
| EV / EBITDA | 60.4x |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 4, 2026, after the close. Analysts expect revenue of $255m and EPS of $0.02 (range −$0.01 to $0.07) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $0.14 | +134% | $1.0bn | +27% |
| Next | $0.37 | +170% | $1.2bn | +19% |
Next year's EPS estimate has moved +4.6% in 90 days, across 11 analysts.
The consensus EPS forecast for the current fiscal year is +6.3% on 90 days ago. In the last 30 days, 0 analysts raised Caris Life Sciences, Inc.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $0.13 | $0.36 |
| 60 days ago | $0.14 | $0.38 |
| 30 days ago | $0.14 | $0.38 |
| 7 days ago | $0.14 | $0.37 |
| Now | $0.14 | $0.37 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.01 | $0.00 | −100.0% |
| Mar 2026 | −$0.02 | $0.00 | +100.0% |
| Dec 2025 | $0.10 | $0.28 | +168.7% |
| Sept 2025 | −$0.14 | $0.08 | +158.8% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2026 to date |
|---|---|
| Return | |
| CAI | +19% |
| Industry peers (median) | +15% |
| S&P 500 | +11% |
| Months that ended higher | |
| CAI | 46% |
| S&P 500 | 46% |
| Largest fall from a high during the year | |
| CAI | −49% |
| S&P 500 | −9% |
Worst fall since June 18, 2025: 63% from August 22, 2025 to May 15, 2026. Getting back needed a 170% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 5, 2026 | +24.2% | −0.4% | +38.3% | +57.3% |
| May 7, 2026 | −15.6% | +0.5% | −20.3% | −15.6% |
| February 26, 2026 | +10.0% | −1.0% | +5.0% | −7.4% |
| January 12, 2026 | −7.4% | 0.0% | −7.9% | −24.6% |
| November 5, 2025 | −21.1% | −0.7% | −20.6% | −7.4% |
| August 12, 2025 | +13.5% | +1.4% | +22.2% | +13.2% |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY24 Q4 | $412.3M |
| FY25 Q1 | $452.5M |
| FY25 Q2 | $533.8M |
| FY25 Q3 | $649.1M |
| FY25 Q4 | $812M |
| FY26 Q1 | $907.3M |
| FY26 Q2 | $989.6M |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY24 Q4 | -62.4% |
| FY25 Q1 | -49.2% |
| FY25 Q2 | -32.6% |
| FY25 Q3 | -12.4% |
| FY25 Q4 | 5.6% |
| FY26 Q1 | 11.9% |
| FY26 Q2 | 15.5% |
Source: SEC EDGAR filings. Retrieved October 20, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY24 Q4 | -61.5% |
| FY25 Q1 | -46.9% |
| FY25 Q2 | -26.3% |
| FY25 Q3 | -2.2% |
| FY25 Q4 | 8.2% |
| FY26 Q1 | 13.6% |
| FY26 Q2 | 12.5% |
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 306 | 412 | 812 | 990 |
| EBITDA | −271 | −208 | 68 | 174 |
| Operating income | −320 | −257 | 45 | 153 |
| Net income | −341 | −282 | −68 | 105 |
| Diluted EPS | −$2.65 | −$2.13 | −$3.22 | — |
| Growth (year on year) | ||||
| Revenue | — | +34.7% | +97.0% | +85.4% |
| Margins | ||||
| EBITDA margin | −88.4% | −50.5% | 8.3% | 17.6% |
| Operating margin | −104.4% | −62.4% | 5.6% | 15.5% |
| Net margin | −111.5% | −68.4% | −8.4% | 10.6% |
| Free-cash-flow margin | −97.5% | −61.5% | 8.2% | 12.5% |
| Cash flow | ||||
| Cash from operations | −276 | −245 | 83 | 169 |
| Capital spending | 22 | 8 | 16 | 45 |
| Free cash flow | −298 | −254 | 67 | 124 |
| Stock-based pay | 15 | 19 | 70 | 65 |
| Free cash flow after stock pay | −314 | −272 | −3 | 59 |
| Balance sheet | ||||
| Cash | — | 64 | 796 | — |
| Total debt | — | 380 | 379 | 393 |
| Net debt (negative = net cash) | — | 316 | −417 | — |
| Diluted shares | 175m | 177m | 167m | — |
| Returned to shareholders | ||||
| Buybacks | 0 | 0 | 0 | 21 |
| Total returned | 0 | 0 | 0 | 21 |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 102 | 130 | 121 | 181 | 217 | 293 | 216 | 264 |
| EBITDA | −50 | −28 | −51 | −12 | 38 | 93 | 10 | 33 |
| Operating income | −61 | −37 | −58 | −18 | 33 | 88 | 5 | 27 |
| Net income | −68 | −37 | −103 | −72 | 24 | 82 | −1 | −1 |
| Diluted EPS | −$2.59 | −$1.74 | −$3.57 | −$7.97 | $0.08 | $1.61 | $0.00 | $0.00 |
| Growth (year on year) | ||||||||
| Revenue | — | — | +49.9% | +81.3% | +113.4% | +125.4% | +78.8% | +45.4% |
| Margins | ||||||||
| EBITDA margin | −49.5% | −21.5% | −42.1% | −6.4% | 17.3% | 31.7% | 4.8% | 12.7% |
| Operating margin | −59.9% | −28.5% | −47.9% | −9.9% | 15.1% | 30.2% | 2.4% | 10.2% |
| Net margin | −66.6% | −28.4% | −84.8% | −39.6% | 11.2% | 28.0% | −0.2% | −0.2% |
| Free-cash-flow margin | −70.1% | −31.7% | −28.1% | 3.3% | 25.5% | 13.6% | 10.4% | 2.4% |
| Cash flow | ||||||||
| Cash from operations | −69 | −39 | −31 | 7 | 62 | 45 | 33 | 28 |
| Capital spending | 2 | 2 | 3 | 1 | 7 | 5 | 10 | 22 |
| Free cash flow | −71 | −41 | −34 | 6 | 55 | 40 | 23 | 6 |
| Stock-based pay | 5 | 5 | 15 | 28 | 14 | 13 | 16 | 22 |
| Free cash flow after stock pay | −76 | −46 | −49 | −22 | 42 | 26 | 7 | −16 |
| Last 12 months unless stated | CAI | INNV | CRVL | PNTG | GH | USPH | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $990m | $990m | $984m | $1.1bn | $1.2bn | $812m | $1.1bn |
| Revenue growth, last 12 months | 85.4% | 15.9% | 7.1% | 37.9% | 42.7% | 11.3% | 7.4% |
| Revenue growth, 3-year average | — | 12.9% | 10.3% | 30.0% | 32.4% | 11.8% | 11.3% |
| Revenue growth, latest quarter | 45.4% | 18.3% | 10.7% | 35.8% | 44.3% | 8.5% | 8.6% |
| Gross margin | — | 23.0% | 24.8% | — | 65.0% | 18.7% | 27.9% |
| Operating margin | 15.5% | 0.3% | — | 5.6% | −39.7% | 9.4% | 2.6% |
| Operating margin, 3-year average | — | −2.1% | — | 5.5% | −58.3% | 9.0% | 2.3% |
| Net margin | 10.6% | −0.3% | 11.7% | 2.9% | −38.3% | 4.0% | 1.2% |
| Cash from operations / revenue | 17.0% | 6.5% | 15.3% | 4.8% | −15.7% | 10.2% | 6.3% |
| Free-cash-flow margin | 12.5% | 5.1% | 11.6% | 3.1% | −20.3% | 7.9% | 5.2% |
| Free-cash-flow margin, 3-year average | — | 0.8% | 10.3% | 3.5% | −33.2% | 9.0% | 3.6% |
| Stock pay / revenue | 6.6% | 0.7% | 0.5% | 0.9% | 16.2% | 1.1% | 1.1% |
| Change in share count | — | 0.2% | −1.2% | 3.6% | 4.6% | 0.2% | 0.3% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Molecular Profiling Services | $767M | 94.4% | ▲ 119.6% |
| Pharma Research and Development Services | $45.3M | 5.6% | ▼ 28.2% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $801M | 98.7% | ▲ 99.4% |
| Outside the US | $10.6M | 1.3% | ▲ 2.1% |
From Caris Life Sciences, Inc.'s 10-K filed March 3, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $551M | 30.9M | 20.1% | ▲ 0.4% |
| J. H. Whitney Equity Partners Vi, LLC | $201M | 11.3M | 7.3% | ▼ 38.3% |
| Coatue Management LLC | $175M | 9.8M | 6.4% | 0.0% |
| Braidwell LP | $147M | 8.3M | 5.4% | ▲ 3.1% |
| Sixth Street Partners Management Company, L.P. | $131M | 7.3M | 4.8% | ▼ 49.1% |
| Pointstate Capital LP | $122M | 6.8M | 4.4% | ▼ 7.2% |
| Jpmorgan Chase & Co | $120M | 6.6M | 4.4% | ▲ 89.5% |
| Blackrock, Inc. | $98.7M | 5.5M | 3.6% | ▲ 14.0% |
| T. Rowe Price Investment Management, Inc. | $90.5M | 5.1M | 3.3% | ▼ 9.1% |
| Vanguard Portfolio Management LLC | $86.3M | 4.8M | 3.1% | ▲ 28.9% |
| Vanguard Capital Management LLC | $76.3M | 4.3M | 2.8% | ▲ 28.6% |
| Los Angeles Capital Management LLC | $70.5M | 4.0M | 2.6% | ▲ 72.9% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Caris Life Sciences, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Denton John Russel See Remarks | September 22, 2026 | Sell | 7,500 | $31.82 | $238,650 |
| Brille Brian J See Remarks | September 17, 2026 | Sell | 400,000 | $30.33 | $12.1M |
| Spetzler David Baxley President | September 4, 2026 | Sell | 119,212 | $24.76 | $3M |
| Spetzler David Baxley President | September 3, 2026 | Sell | 84,900 | $25.32 | $2.1M |
| Spetzler David Baxley President | September 3, 2026 | Sell | 393,100 | $24.76 | $9.7M |
| Halbert Jon Director | May 15, 2026 | Buy | 68,000 | $14.56 | $990,080 |
| Vacirca Jeff L Director | May 11, 2026 | Buy | 31,050 | $16.15 | $501,457 |
| Power Luke Thomas See Remarks | December 11, 2025 | Sell pre-set plan | 60,850 | $26.56 | $1.6M |
| Power Luke Thomas See Remarks | December 11, 2025 | Sell pre-set plan | 1,400 | $27.16 | $38,024 |
| Spetzler David Baxley President | November 7, 2025 | Buy | 400 | $23.85 | $9,540 |
| Denton John Russel See Remarks | November 7, 2025 | Buy | 4,184 | $24.09 | $100,793 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around October 14, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
